Eli
Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies
Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases
Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage
Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit
Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing
Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.
NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach
NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide
Eli Lilly Invests $4.5 Billion in Groundbreaking Indiana Manufacturing and R&D Facility
Eli Lilly, pharmaceutical manufacturing, R&D, Indiana, Lilly Medicine Foundry, clinical trials, drug development
Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera
Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates
Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market
Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry
FDA Approves Lilly’s Ebglyss for Moderate-to-Severe Atopic Dermatitis
Ebglyss, atopic dermatitis, eczema, FDA approval, Eli Lilly, lebrikizumab, biologic treatment